Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Raik Schneider"'
Autor:
Raik Schneider, Günther Gademann, Hans-Joachim Ochel, Karsten Neumann, Burkhard Jandrig, Peter Hass, Mathias Walke, Martin Schostak, Thomas Brunner, Frank Christoph
Publikováno v:
Radiation Oncology, Vol 16, Iss 1, Pp 1-11 (2021)
Abstract Background Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but cli
Externí odkaz:
https://doaj.org/article/6ec71033d66d40c4ae7284bdf61dce0a
Autor:
Peter Hass, Karsten Neumann, Thomas Brunner, Martin Schostak, Mathias Walke, Hans-Joachim Ochel, Günther Gademann, Raik Schneider, Burkhard Jandrig, Frank Christoph
Publikováno v:
Radiation Oncology, Vol 16, Iss 1, Pp 1-11 (2021)
Radiation Oncology (London, England)
Radiation Oncology (London, England)
Background Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but clinical dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24e6af7a35bc7106ba9b7271ae249071
https://doi.org/10.1186/s13014-021-01859-6
https://doi.org/10.1186/s13014-021-01859-6
Autor:
Raik Schneider, Hans-Joachim Ochel, Karsten Neumann, Burkhard Jandrig, Peter Hass, Matthias Wahlke, Martin Schostak, Thomas Brunner, Frank Christoph, Guenther Gademann
Background: The EGF-receptor is often overexpressed in advanced prostate carcinoma. In-vitro studies in prostate carcinoma cell-line DU145 demonstrated increased sensibilities to radiation with Cetuximab; in-vivo effects were not detected. Methods: I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d641c3cb926f21649c1e9eb67bb5236f
https://doi.org/10.21203/rs.2.18709/v1
https://doi.org/10.21203/rs.2.18709/v1
